10-YEARS EXPERIENCE OF ETANERCEPT USE IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHELYABINSK REGIONAL PEDIATRIC HOSPITAL

Galina Glazyrina1,2, Olga Sudareva3.

AB0981

Methods: 51 children aged from 3 to 17 (mean age 10,0 years) diagnosed with JIA were under monitoring (12 boys, 39 girls). Disease duration was from 2 to 15 years (mean duration 5,4 years). JIA was diagnosed based on ILAR diagnostic criteria. Oligo arthritis was diagnosed in 9 children, sero-negative polyarthritis was diagnosed in 34 children. 3 patients had systemic JIA (without active systemic presentations), 11 children. In all children methotrexate was ineffective in dose of 15 mg/m² during 6-12 months. Etanercept was introduced in dose of 0.8 mg KW. Therapy duration was from 3 months to 8 years (mean duration 29 months). Assessment of disease activity and therapy efficiency was conducted in accordance with ACR pedi criteria. Nonparametric statistical methods were used to compare results.

Results: Prior to etanercept use high disease activity was observed in all children. Mean number of joints with active arthritis was 8 [4, 10] (Me[25;75%]). Mean number of joints with functional impairments – 4 [2;10]. Mean ESR (according to Panchenkov) – 23 [10;35] mm/h, CRP 12.0 [5;73] g/L. Assessment of functional activity according to CHAQ questionnaire – 1,25 [1;2]. Activity assessment according to VAS by doctor – 70 [60;70]. Assessment of parents/patients according to VAS 70 [50;90]. No active systemic presentations and eye lesions were found in children under monitoring.

On the background of etanercept therapy a decrease in disease activity was observed in 50 patients. Mean number of joints with active arthritis was 0 [0;2] (Me[25;75%]) (P<0.0001). Mean number of joints with functional impairments – 0 [0;2] (P<0.0001). Mean ESR was 5 [3;6] mm/h (P<0.0001), CRP 3 [2;4] g/L (P<0.0001). Assessment of functional activity according to CHAQ questionnaire was 0,125 [0,0;0,5] (P<0.0001). Activity assessment according to VAS by doctor – 10 [5;20] (P<0.0001). Assessment of parents according to VAS 10 [5;20] (P<0.0001).

Clinical disease remission (according to ACR pedi criteria >90%) was observed in 32 patients after 6-12 months of treatment. Remission duration up to now is from 1 to 7 years. Efficiency according to ACR pedi criteria is 70% in 11 children, 50% in 5, 30% in 2.

Etanercept was well-tolerated. Drug was cancelled in 9 patients. 6 patient (11.8%) developed bilateral uveitis, one patient had an allergic reaction (rash), one - systemic manifestations, one - urinary tract infection. There were no cases of tuberculosis.

Conclusion: Etanercept therapy was highly effective and safe in patients with JIA. Clinical remission was achieved in 62.7% children. Decrease in disease activity was observed in 98% of children. 11,8% patient developed uveitis, on average, after a year of using etanercept.

REFERENCES


Disclosure of Interests: None declared

AB0982

CENTRAL NERVOUS SYSTEM ANGIITIS: THE EXPERIENCE OF A TERTIARY RHEUMATOLOGY BRAZILIAN CENTER

Francisco Hugo Rodrigues Gomezi, Camilla Maria Viana Balista2, Jose Sávio Menezes Parente3, Luana Coelho Benevides1, Milena Fozer Leite1, Virginia Ferriani1, Luciana Martins de Carvalho1. 1University of Sao Paulo, Department of Pediatrics, Division of Pediatric Rheumatology, Ribeirão Preto, Brazil; 2University of Sao Paulo, Department of Pediatrics, Ribeirão Preto, Brazil

Background: Central nervous system (CNS) angiitis is a severe and rare inflammatory brain disease whose course varies from patient to patient. May be associated with infections, malignances, metabolic diseases or systemic collagen vascular disorders. It is classified as primary or idiopathic in the absence of associated systemic diseases. The exact incidence is still undetermined.

Objectives: To describe the clinical and laboratory data, the response to therapy and outcome of patients with CNS angiitis seen at a Tertiary Pediatric Rheumatology Center.

Methods: This is a retrospective, single-center chart review study of pediatric patients with clinical diagnoses of CNS angiitis, followed up in a Tertiary Pediatric Rheumatology Center, from January 2009 to December 2018. Diagnosis was confirmed by magnetic resonance angiography (MRA) or after exhaustive exclusion of other causes.

Results: Nine patients (4 girls) were enrolled in this study. Mean age at inclusion and at diagnosis was 11.5 years (7.8 to 19.9) and 8 years (3.5 to 12.5), respectively. Among the 9 patients, 4(44%) were diagnosed with primary CNS angiitis, Polyarteritis nodosa (n=4), Polyarteritis disease (n=1) were the aetiologies of secondary CNS angiitis. Main clinical features were sudden onset of seizures (67%) and headache (55%). Other important symptoms were: decreased level of consciousness, hemiparesis and neurocognitive dysfunction. In the cerebral spinal fluid, protein was elevated in 22% of patients. The pattern of lesions was bilateral in 67% and multifocal in 55%, being suggestive of ischemic lesions by CNS magnetic resonance in 78% of the cases. The MRA was conclusive in all cases of secondary and normal in only one case of primary CNS angiitis. Increased erythrocyte sedimentation rate, C-reactive protein and leukocyte count were more frequently observed in patients with secondary CNS angiitis as compared to patients with primary angiitis. In one case of primary CNS angiitis with negative vascular study, the Von Willebrand factor antigen was positive, being useful in the differential diagnosis. Steroids were administered in 100% of patients, associated with immunosuppressants in 7/9 cases. Induction therapy with intravenous cyclophosphamide was used in 78% of the cases and in the maintenance phase, azathioprine in 78% of them. No relapses occurred. The most commonly clinical sequel observed was residual epilepsy (55%).

Conclusion: In this study, seizures were the most frequently symptom found. Steroids plus immunosuppressants were effective in the disease control. MRA was positive in all cases of secondary CNS angiitis, being effective in the diagnosis of this condition. Recognition of findings and adequate diagnosis guides the treatment, which should be specific to the underlying cause, aiming to provide a good neurologic outcome.

REFERENCES


Disclosure of Interests: None declared

AB0983

PENTraxIN 3 AS A MARKER OF DISEASE ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS

Waleed Hassan1, Eman Benhii2, Shorouk Abdelshafy3. 1Benha University, Rheumatology and Rehabilitation, Benha, Egypt; 2Benha University, Clinical and Chemical Pathology, Benha, Egypt; 3Benha University, Diagnostic Radiology, Benha, Egypt

Background: Pentraxin-3 (PTX3) is a secretory acute phase protein which is produced and expressed in many immune cells especially macrophages, fibroblasts and endothelial cells at different inflammatory sites [1].

REFERENCES


Disclosure of Interests: None declared
PTX3 is known to have an interesting role in regulation of innate immunity and it is a key player in regulation of many inflammatory reactions [3].

Objectives: This study aimed to measure serum and synovial fluid (SF) levels of PTX3 in juvenile idiopathic arthritis (JIA) patients and to correlate them with different clinical, laboratory and musculoskeletal ultrasound parameters of disease activity.

Methods: We measured PTX3 in the serum (n=57) and SF samples (n=18) from 57 JIA patients and in the serum from twenty healthy control. Disease activity was calculated using the Juvenile Arthritis Disease Activity Score in 27 joints (JADAS27) and musculoskeletal ultrasound examination (MSUS) was performed using grey scale (GS) and power Doppler (PD) 10-joint score (bilateral knee, ankle, wrist, elbow and the 2nd metacarpophalangeal (MCP) joints)[3]; Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, serum ferritin, rheumatoid factor (RF) titre were measured and the Juvenile arthritis multidimensional assessment report (JAMAR) was documented.

Results: Serum PTX3 level was significantly higher in JIA patients (3.59± 2.38 ng/mL) compared to serum level in the healthy controls (1.5 ± 0.9 ng/mL) (p<0.001). There was no significant difference between SF PTX3 level (4.73 ± 2.62 ng/mL) and its level in paired serum samples (4.23± 2.93 ng/mL) (p=0.59). JIA patients with systemic onset subtype (n=13) had higher PTX3 serum levels (5.57± 2.52 ng/mL) compared to serum level in the oligoarticular (n=25) and polyarticular (n=19) subtypes (2.88± 2.13 ng/mL and 3.18±1.12 ng/mL respectively) (p=0.001 and 0.005 respectively). In JIA patients, serum PTX3 level significantly correlated with JADAS27 (r=0.52, p<0.05), CRP titre (r=0.46, p<0.05) and serum ferritin (r=0.48, p<0.05). Both serum and SF PTX3 levels significantly correlated with PD score (r=0.51 and 0.48 respectively, p<0.05). SF PTX3 (p =0.001) was shown to be superior to serum PTX3 (p =0.02), ESR (p =0.07) and comparable to CRP (p =0.001) at predicting PD synovitis score.

Conclusion: JIA patients have significantly increased serum and synovial fluid levels of Pentraxin 3 that remarkably correlated with the JADAS27 and MSUS parameters of inflammations suggesting that it could be a useful marker to reflect JIA disease activity.

REFERENCES

Disclosure of Interests: None declared

AB0984 INTERSTITIAL LUNG DISEASE IN CHINESE JIA PATIENTS
Assunta Ho, Kate Chan, Li Albert, Prince of Wales Hospital, The Chinese University of Hong Kong, Paediatrics, Hong Kong, Hong Kong (SAR)

Background: Rheumatic diseases and or medications (for example methotrexate) used to treat the underlying condition are associated with the development of interstitial lung disease (ILD). Development of ILD in subjects with juvenile idiopathic arthritis (JIA) is assumed to be rare, however, severe respiratory complications are increasingly reported in JIA patients.

Objectives: To describe the prevalence of respiratory diagnoses and ILD in a group of Chinese JIA patients at a tertiary center.

Methods: Retrospective chart review of JIA patients attending rheumatology clinic during 2012 to 2019.

Results: Fifty-eight cases of JIA were identified. Thirty-three (57%) received DMARDs, majority were on methotrexate (MTx, 24, 73%) and sulphasalazine (SSZ, 14, 42%). Eleven (19%) were currently or previously on biologics (adalimumab 5, etanercept 5, anakinra 1, previous exposure: infliximab 1, etanercept and anakinra 1). Respiratory diagnosis was made in 11 (19%) patients. There were 2 (3.4%) cases of ILD diagnosed during the study period (see below). The rest were ashenmatics. Among them, 9 were on DMARDs [MTx (8/9%), SSZ (4/4%), leflunomide 2 (LEF), hydroxychloroquine 1 (HCQ)] or biologics [Etanercept 3 (33%), adalimumab 1, tocilizumab and anakinra 1 (sequential)]. Four subjects were on combination DMARDs [MTx&SSZ in 2, 1 each for MTx+LEF+HCQ+SSZ (sequential combination)& MTx+LEF]. Three received combination DMARDs and biologics (1 each for MTx+adalimumab, MTx+etanercept & MTx+anakinra).

Cases of ILD
One was a SJA patient diagnosed at 2 years old. She failed methotre- xate, etanercept & tocilizumab (infusion reaction). She was on low dose prednisolone, methotrexate and anakinra when she presented to us with acute right heart failure requiring ICU care 3 years after diagnosis. Advanced clubbing was noted (fig 1). HRCT thorax on presentation showed severe interstitial lung disease with marked fibrosis and traction bronchiectasis (fig 2). She was diagnosed acute on chronic cor pulmo- nale and pulmonary hypertension secondary to ILD. The other was an oligoarticular JIA patient, diagnosed at 2 years old. She was refractory to intra-articular steroid injections and combination DMARDs including MTx, SSZ, LEF & HCQ. Arthritis was controlled by Etanercept. At 12 years of age, she started to have chest pain. Lung function test showed restrictive lung pattern. HRCT thorax showed pulmonary fibrosis.

Conclusion: From this Chinese cohort we identified 2 cases of ILD. They did not present with any symptoms until advanced stage or when complications set in. Both were very young at diagnosis and were difficult to control, as evidenced by the use of multiple DMARDs and biologics including methotrexate, IL6 and IL1 blockade. The causes of ILD are believed to be multifactorial. For severe case, prognosis is poor1. Although rare, methotrexate induced pneumonitis do occur.

Symptoms of ILD may not be obvious until late stage. Clinical examination alone is not sensitive enough to detect disease progression. Asthma is common, as in this cohort, and may further complicated the assessment. It is recommended in the recent SHARE initiative on JSLE to screen for lung disease2. We believe it should be performed in JIA patients as well. 6 minute walk test is a noninvasive way to assess cardio-pulmonary functional status and is validated in children3. Patients with unexplained chest symptoms or impaired lung function should be referred to pulmonologist for further assessment.

REFERENCES

Figure 1